Clinical Trials Sponsored by Workforce Development, Inc.

Total 1137 results

Midwest Evaluation & Research
Fresno Area Workforce Development Board (FAWDB)

Recruiting

Fresno FAWDB FIRE Program Evaluation

Fathers

United States
Mathematica Policy Research, Inc.
Minnesota Department of Health; Social Security Administration; Department of... and other collaborators

Recruiting

Minnesota RETAIN Impact Evaluation

Any Injury or Illness Acutely Impacting Work

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Xilio Development, Inc.

Recruiting

XTX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Rectal Cancer | Colon Cancer

Argentina, Russian Federation, United States, Australia, Brazil, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Ovarian Cancer

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Belgium, Italy, Spain, United States, Ukraine, United Kingdom
Labcorp Drug Development Inc

Recruiting

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (PREFER)

Melanoma | Soft Tissue Sarcoma | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Rhabdomyosarcoma | Uterine Cancer

United States
Sunovion Respiratory Development Inc.

Completed

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease (COPD)

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-3)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-5)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Czechia, Hungary, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Belgium, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Education Development Center, Inc.

Unknown

Addressing Proven Factors in HIV Prevention for Latino Youth

HIV | Sexually Transmitted Infections
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Education Development Center, Inc.

Completed

Reducing HIV Risks in African American Teens

HIV Infections

United States
Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (GOLDEN-4)

Chronic Obstructive Pulmonary Disease | COPD

United States
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
C.T. Development America, Inc.

Completed

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Amyloidosis

Spain, United States, Italy, Belgium, Netherlands, India, Tunisia, Latvia, Turkey, France, Germany, Estonia, Lithuania, Poland, Russian Federation, Georgia, United Kingdom, Israel, Egypt, Finland, Peru, Sweden, Ukraine
C.T. Development America, Inc.

Completed

A Study of RX-10045 in the Treatment of Dry Eye Disease

Dry Eye Syndrome

United States
C.T. Development America, Inc.

Completed

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Education Development Center, Inc.

Completed

Parent Education for Young Teen Females

Prevention

United States
Alimentiv Inc.
Takeda Development Center Americas, Inc.

Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)

Colitis, Ulcerative

Canada, United Kingdom, Poland, Italy, United States, Belgium, France, Netherlands, Belarus, Ukraine
Aurinia Pharmaceuticals Inc.
Labcorp Drug Development Inc

Recruiting

Voclosporin in Adolescents With Lupus Nephritis (VOCAL)

Adolescent Lupus Nephritis

United States
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (JUNIPER)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Bulgaria, France, Poland
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Poland, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Post Traumatic Stress Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

Smoking Cessation

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Borderline Personality Disorder

United States, Spain, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Drug-drug Interaction

Australia
Ironshore Pharmaceuticals and Development, Inc

Completed

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Attention-Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States

Clinical Trials Sponsored by Workforce Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations